Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC-TACE and Donafenib in BCLC B Hepatocellular Carcinoma
NCT05171166Phase 3Terminated
- Sponsor
- Peking University
- Start
- Dec 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Peking University. Started Dec 2021; status: terminated.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05171166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171166.